Controlling cardiovascular risk factors and maintaining long-term disease remission mitigated the increased risk for ...

RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Antiphospholipid Syndrome.

The primary safety endpoints are toxicities — including cytokine release syndrome, ICANS, organ toxicity and hematotoxicity, at grade 2 or higher for all — while efficacy endpoints are DORIS ...

β 2-glycoprotein I (β 2-GPI) is a natural inhibitor of the platelet-VWF interaction. The antiphospholipid syndrome (APS) is associated with thrombosis, with an important pathophysiological role of ...

Catastrophic antiphospholipid syndrome (CAPS) is a rare and life threatening complication of antiphospholipid syndrome. Up to half of people with CAPS die, so timely treatment is essential.